Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed

Inclusion Criteria: * Able to give informed consent and comply with the study * Diagnosis of osteoarthritis (OA) in the index knee * Combined WOMAC A (pain) and C (function) subscale score of ≥ 23 at screening, using the WOMAC 5-point Likert scale * Eligible for total knee replacement (TKR) surgery but unable to schedule surgery or undergo scheduled surgery * In good general health; American Society of Anesthesiologists (ASA) physical status category ≤3 * Willing to use contraception for at least 30 days after receiving the study drug * Able to understand and complete study-related forms and adequately communicate with the Investigator and site staff Exclusion Criteria: * Pre-existing osteonecrosis, subchondral insufficiency fracture, or knee pain attributable to disease other than OA which may confound the ability to assess response to treatment * Concurrent medical or arthritic conditions that could interfere with evaluation of the index knee joint including, metabolic diseases, gout/pseudogout, hemochromatosis, acromegaly, fibromyalgia, rheumatoid arthritis, or other inflammatory arthropathies affecting the knee joint * Participants with significant pain in the back or other joints (ex. hip pain) which may confound discrimination of pain assessment in index knee, as judged by the Investigator * Undergone arthroscopic surgery of the index knee within 6 months of study drug administration, or open surgery to the index knee within 24 months of study drug administration * Undergone replacement surgery of the index knee * Presence of surgical hardware or other foreign bodies in the index knee * Index knee injections with corticosteroids within 30 days, or hyaluronic acid within 3 months, or platelet-rich plasma within 6 months prior to study drug administration. * Concurrent use of opioids for indications other than knee pain * Arterial or venous thrombi (including stroke), myocardial infarction, hospital admission for unstable angina, cardiac angioplasty, or stenting within 12 months prior to Screening. * Sensory peripheral neuropathy in the distal aspect of the target limb that is of moderate severity or higher at Screening * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or hepatitis C; positive tests for HIV-1 or -2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies * Specified laboratory abnormalities within 1 week of study drug administration * Hist…